TriSalus Life Sciences (NASDAQ:TLSI) Posts Quarterly Earnings Results, Misses Estimates By $0.08 EPS

TriSalus Life Sciences (NASDAQ:TLSI) announced its earnings results on Thursday. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08), FiscalAI reports. The firm had revenue of $13.21 million during the quarter, compared to analysts’ expectations of $13.20 million.

TriSalus Life Sciences Trading Down 4.6%

TLSI stock traded down $0.23 during midday trading on Thursday, hitting $4.77. 247,820 shares of the company’s stock were exchanged, compared to its average volume of 159,872. TriSalus Life Sciences has a 1-year low of $3.42 and a 1-year high of $7.95. The business has a 50-day simple moving average of $5.46 and a two-hundred day simple moving average of $5.36. The stock has a market capitalization of $238.79 million, a PE ratio of -2.36 and a beta of 0.42.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Wall Street Zen cut TriSalus Life Sciences from a “hold” rating to a “sell” rating in a report on Sunday, February 8th. Weiss Ratings restated a “sell (e+)” rating on shares of TriSalus Life Sciences in a report on Monday, December 29th. Canaccord Genuity Group increased their target price on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Finally, Zacks Research upgraded shares of TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, December 16th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $12.00.

Institutional Trading of TriSalus Life Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. acquired a new stake in shares of TriSalus Life Sciences in the fourth quarter valued at $72,000. Man Group plc purchased a new stake in TriSalus Life Sciences during the fourth quarter worth about $102,000. Abel Hall LLC purchased a new stake in TriSalus Life Sciences during the fourth quarter worth about $73,000. Kotler Kevin purchased a new stake in TriSalus Life Sciences during the 4th quarter worth approximately $1,013,000. Finally, Price T Rowe Associates Inc. MD purchased a new position in TriSalus Life Sciences in the 4th quarter valued at approximately $104,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.